Indivior Pharmaceuticals Inc — Bilancio Trimestrale (NASDAQ:INDV) | MetaTrader

Apri il grafico completo

Indivior Pharmaceuticals Inc

Indivior is an American pharmaceuticals company. Established as a division of Reckitt Benckiser in 1994 and demerged from that company in December 2014, it is focussed on substitution products for opioid addiction. It is listed on the London Stock Exchange and on the NASDAQ Global Select Market.

Notizie

CGON Stock Up 60.8% in Six Months: Here's What You Need to Know

KYMR Stock Up as FDA Grants Fast Track Designation to Asthma Drug

RVMD Stock Rallies 41% on Positive Phase III Pancreatic Cancer Data

ALLO Rises on Strong MRD Clearance With Cema-Cel in ALPHA3 Study

Cipher Mining Stock, Five Below, Indivior Among 10 New Stocks On IBD Watchlists

SNY & REGN's Dupixent Gets EU Approval for Pediatric Use in Urticaria

ASML, An AI Megatrend Star, Leads 8 Newcomers To Best Stock Lists

IBRX Stock Rises 7% on Strong Q1 2026 Preliminary Results

KYMR Set to Earn Milestone Payment as GILD Secures License for KT-200

How Much Upside is Left in Indivior Pharmaceuticals Inc. (INDV)? Wall Street Analysts Think 45.99%

ACIU Stock Rallies 16.3% in a Week: Here's What You Need to Know

Soleno Therapeutics Stock Rallies 56.4% in a Week: Here's Why